HC Wainwright Reaffirms Buy Rating for Senseonics (NYSE:SENS)

HC Wainwright reiterated their buy rating on shares of Senseonics (NYSE:SENS) in a research report report published on Wednesday,Benzinga reports. HC Wainwright currently has a $2.00 target price on the stock.

Separately, StockNews.com assumed coverage on shares of Senseonics in a report on Thursday, December 26th. They set a “sell” rating on the stock.

Senseonics Stock Down 1.3 %

SENS stock opened at $0.69 on Wednesday. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. Senseonics has a twelve month low of $0.25 and a twelve month high of $1.40. The company’s 50 day moving average is $0.86 and its two-hundred day moving average is $0.53. The stock has a market cap of $412.56 million, a P/E ratio of -5.33 and a beta of 1.17.

Senseonics (NYSE:SENS) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.09). Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. During the same quarter last year, the firm posted ($0.07) EPS. Research analysts expect that Senseonics will post -0.14 earnings per share for the current fiscal year.

Insider Activity

In other Senseonics news, CEO Timothy T. Goodnow bought 315,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were acquired at an average cost of $0.31 per share, with a total value of $97,650.00. Following the acquisition, the chief executive officer now directly owns 11,310,355 shares of the company’s stock, valued at $3,506,210.05. The trade was a 2.86 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Frederick T. Sullivan bought 124,933 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the completion of the acquisition, the chief financial officer now directly owns 2,478,844 shares in the company, valued at approximately $941,960.72. This trade represents a 5.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Senseonics

A number of institutional investors have recently modified their holdings of SENS. First Light Asset Management LLC acquired a new position in shares of Senseonics in the 4th quarter valued at $3,366,000. Jane Street Group LLC grew its position in Senseonics by 6,694.1% in the 4th quarter. Jane Street Group LLC now owns 6,118,786 shares of the company’s stock valued at $3,203,000 after buying an additional 6,028,726 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Senseonics in the 4th quarter valued at $720,000. Millennium Management LLC grew its position in Senseonics by 299.0% in the 4th quarter. Millennium Management LLC now owns 1,088,029 shares of the company’s stock valued at $569,000 after buying an additional 815,332 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Senseonics by 9.7% in the 4th quarter. Geode Capital Management LLC now owns 6,405,100 shares of the company’s stock valued at $3,354,000 after buying an additional 566,704 shares during the last quarter. 12.36% of the stock is owned by institutional investors and hedge funds.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.